Podrid P J, Lyakishev A, Lown B, Mazur N
Circulation. 1980 Feb;61(2):450-7. doi: 10.1161/01.cir.61.2.450.
Ethmozin, a phenothiazine derivative, is an antiarrhythmic drug synthesized in the USSR. Preliminary data suggest that it is effective against a diversity of ectopic arrhythmias. The present study, carried out in the USSR, was designed to assess efficacy and patient tolerance of this new drug. Thirty-seven patients with chronic, persistent, frequent and symptomatic ventricular premature complexes (VPCs) were studied. VPCs were exposed by means of 24-hour ambulatory monitoring and exercise stress testing. Two drug schedules were used. Group 1, consisting of 11 patients, received 225 mg/day of ethmozin, while group 2, consisting of 26 patients, received 600 mg/day. Acute drug testing with a single large dose of ethmozin was followed by multiple dosing for a minimum of 4 days. Placebo was given in a single-blind fashion only to responders. Only two patients in group 1 had a significant reduction in VPCs as evaluated by both monitoring and exercise testing. Fourteen patients in group 2 (54%) showed striking suppression of VPCs. Mild and transiet effects were encountered in only four of the 37 patients. We conclude that ethmozin appears to be a well-tolerated, relatively effective agent for controlling VPCs.
乙吗噻嗪是一种吩噻嗪衍生物，是苏联合成的一种抗心律失常药物。初步数据表明，它对多种异位性心律失常有效。在苏联进行的本研究旨在评估这种新药的疗效和患者耐受性。对37例慢性、持续性、频发且有症状的室性早搏（VPC）患者进行了研究。通过24小时动态监测和运动应激试验来检测VPC。采用了两种给药方案。第1组由11例患者组成，接受乙吗噻嗪225毫克/天的剂量，而第2组由26例患者组成，接受600毫克/天的剂量。在单次大剂量乙吗噻嗪急性药物试验后进行多次给药，至少持续4天。仅对有反应者采用单盲方式给予安慰剂。通过监测和运动试验评估，第1组只有2例患者的VPC有显著减少。第2组有14例患者（54%）的VPC受到显著抑制。37例患者中只有4例出现轻微和短暂的效应。我们得出结论，乙吗噻嗪似乎是一种耐受性良好、相对有效的控制VPC的药物。
